Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
iSpecimen Inc (ISPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ISPC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.58% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.47M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.7 | 52 Weeks Range 0.85 - 11.80 | Updated Date 07/4/2025 |
52 Weeks Range 0.85 - 11.80 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -139.65% | Operating Margin (TTM) -154.93% |
Management Effectiveness
Return on Assets (TTM) -73.4% | Return on Equity (TTM) -265.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1989473 | Price to Sales(TTM) 0.31 |
Enterprise Value 1989473 | Price to Sales(TTM) 0.31 | ||
Enterprise Value to Revenue 0.25 | Enterprise Value to EBITDA 0.43 | Shares Outstanding 2496860 | Shares Floating 2455583 |
Shares Outstanding 2496860 | Shares Floating 2455583 | ||
Percent Insiders 2.71 | Percent Institutions 2.41 |
Upturn AI SWOT
iSpecimen Inc
Company Overview
History and Background
iSpecimen Inc. was founded in 2009. It provides an online marketplace for human biospecimens, connecting researchers with a network of healthcare providers. It has evolved from a specimen sourcing company to a technology platform.
Core Business Areas
- iSpecimen Marketplace: An online platform connecting researchers with biobanks and healthcare organizations to source human biospecimens and related clinical data. This segment is the core revenue driver.
- iSpecimen Provider Solutions: Provides technology and services to help healthcare organizations and biobanks manage and market their biospecimen inventories.
Leadership and Structure
Christopher Ianelli, MD, PhD is the CEO. The company has a typical corporate structure with departments such as sales, marketing, operations, and technology.
Top Products and Market Share
Key Offerings
- Human Biospecimens: iSpecimen's core offering consists of various types of human biospecimens (e.g., blood, tissue, cells, DNA/RNA), including diseased and normal samples. iSpecimen's market share is not publicly available. Competitors include companies like BioIVT and Precision for Medicine, which also offer biospecimen sourcing services. Revenue is derived from fees charged per specimen and related data.
- iSpecimen Marketplace Platform: The platform itself is a key offering, enabling researchers and suppliers to easily find and procure specimens. While revenue from platform subscriptions is not broken out, it is a supplementary source of income. Competitors in platform-based biospecimen procurement are less direct, but include organizations that operate their own internal networks for sourcing samples.
Market Dynamics
Industry Overview
The human biospecimen market is driven by increasing research and development in pharmaceuticals, diagnostics, and personalized medicine. Key trends include a growing demand for high-quality, well-characterized specimens and an increased focus on ethical and regulatory compliance.
Positioning
iSpecimen positions itself as a technology-enabled marketplace, offering a more efficient and transparent way to source biospecimens compared to traditional methods. Its competitive advantage lies in its extensive network of suppliers and its data-rich platform.
Total Addressable Market (TAM)
The global biospecimen market is projected to reach over $50 billion by 2030. iSpecimen is positioned to capture a portion of this market by providing a platform that simplifies specimen sourcing. Penetration percentage is in the small single digits.
Upturn SWOT Analysis
Strengths
- Extensive network of biospecimen providers
- Technology platform for efficient sourcing
- Data-rich specimens with clinical information
- Established brand and reputation
Weaknesses
- Dependence on third-party suppliers
- Limited control over specimen quality
- Relatively small market share
- Competition from larger, more established players
Opportunities
- Expansion into new therapeutic areas
- Development of new platform features and services
- Partnerships with pharmaceutical companies and research institutions
- Increased adoption of personalized medicine
Threats
- Economic downturn impacting research funding
- Regulatory changes affecting biospecimen sourcing
- Increased competition from new entrants
- Ethical concerns surrounding biospecimen use
Competitors and Market Share
Key Competitors
- BioIVT
- Precision for Medicine
- Thermo Fisher Scientific (TMO)
Competitive Landscape
iSpecimen's advantages include its technology platform and extensive network, but it faces competition from larger companies with more resources and established relationships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on financial data and is not available in this response.
Future Projections: Future projections are dependent on financial data and analyst estimates and are not available in this response.
Recent Initiatives: Recent initiatives include expanding its provider network and launching new platform features.
Summary
iSpecimen Inc. is a growing player in the biospecimen marketplace, leveraging its technology platform to connect researchers with suppliers. The company faces competition from larger, more established players, and is dependent on third-party suppliers. Its strengths lie in its network and platform, but it needs to address concerns about specimen quality and control.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data and competitor information are based on publicly available sources and estimates, and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iSpecimen Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-06-17 | CEO, Treasurer, Secretary & Director Mr. Robert Bradley Lim | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 24 | Website https://ispecimen.com |
Full time employees 24 | Website https://ispecimen.com | ||
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. The company serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.